Cidara Therapeutics (CDTX) announced its plans to commence an underwritten public offering, subject to market and other conditions, to issue and sell $250M of shares of its common stock. All of the shares are being offered by Cidara. J.P. Morgan, Morgan Stanley, Guggenheim Securities and Cantor are acting as joint book-running managers for the proposed offering.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDTX:
- Cidara Therapeutics Reports Positive Phase 2b Trial Results
- Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!
- Cidara Therapeutics price target raised to $53 from $41 at H.C. Wainwright
- U.S. strikes Iran nuclear sites, Novo terminates Hims & Hers deal: Morning Buzz
- Cidara Therapeutics price target raised to $75 from $35 at RBC Capital